Immunophotonics
Business Services · Missouri, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
4340 Duncan Ave Ste 212, Saint Louis, Mi...Phone Number
(314) 501-1919Website
www.immunophotonics.comRevenue
<$5 MillionIndustry
About Immunophotonics
Immunophotonics is a privately owned clinical-stage biotech company that is pioneering the burgeoning field of Interventional Immuno-Oncology® through the development of novel treatments for solid-tumor cancers. IP-001, the first asset from the company’s intellectual property platform, has the potential to transform a routine tumor ablation into a systemically active cancer immunotherapy. Immunophotonics is also exploring the use of its technology platform to help prevent and combat contractions of infectious diseases. Immunophotonics is headquartered in St. Louis, Missouri, with a subsidiary in Bern, Switzerland.Explore more
Immunophotonics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Immunophotonics
Compare insights from companies similar to Immunophotonics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Immunophotonics Tech Stack
A closer look at the technologies used by Immunophotonics
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Immunophotonics
Sign Up For FreeTo access detailed company insights
Immunophotonics is a privately owned clinical-stage biotech company that is pioneering the burgeoning field of Interventional Immuno-Oncology® through the development of novel treatments for solid-tumor cancers. IP-001, the first asset from the company’s intellectual property platform, has the potential to transform a routine tumor ablation into a... Read More
